Vaccines in America in 2026

There were a number of FDA approvals in recent weeks. Here is a listing of the approvals including the news reports and review of the phase 3 study data.

An FDA advisory committee voted unanimously to recommend mRNA-1010 for approval, after the Agency initially refused to review the application and HHS cancelled contracts supporting mRNA vaccine development.

Invivyd has dosed the first participants in LIBERTY, a phase 3 trial comparing VYD2311 to an mRNA COVID vaccine and coadministration, as the BLA-enabling DECLARATION trial completes enrollment.

Modeling of the ACIP recommendation to replace universal birth-dose HepB vaccination with vaccination based on "shared decision" and maternal status shows substantially more maternal screening or vaccinating infants of unscreened mothers will be necessary to mitigate increase in infections.

Editor-in-Chief Jason Gallagher, PharmD, FCCP, FIDP, FIDSA, BCPS, discusses how a coalition of major medical professional societies needed to step in to sue the federal government after sweeping changes to US vaccine policy under Health and Human Services Secretary Robert F. Kennedy Jr. reshaped the CDC’s vaccine advisory process. The medical organizations argued that the evidence-based foundations of public health recommendations had been compromised.

In this month's column, we talk to leaders from professional medical organizations about the revised Advisory Committee on Immunization Practices charter as well as commentary about the Centers for Disease Control and Prevention’s suppression of COVID-19 vaccine data.

Robert Hopkins Jr, MD, medical director of the National Foundation for Infectious Diseases (NFID), discusses the need to be transparent and publish the latest vaccine data, and offers clinical insights around their safety and efficacy.

In this month's column, a federal district court struck down the

In the second episode with Jason M. Goldman, MD, MACP, immediate past president of the American College of Physicians, he discusses the federal government's attempts to suppress studies on vaccine data and how it continues the ongoing antivaccine ideology with further mis- and disinformation.

Jason M. Goldman, MD, MACP, immediate past president of the American College of Physicians, offers insights on what the changing Advisory Committee on Immunization Practices charter means and legal steps the college is taking to prevent the federal government’s attempt to reshape the group and vaccine policy in the US.

The latest CDC numbers show only a 0.40% increase of measles cases from week-to-week. This continues a downward trend in the percentage of cases from last week where there was only a 2.57% increase.

The latest CDC numbers show a 2.57% increase of measles cases from week-to-week. This is a significant decrease in the percentage of cases from last week where there was a 6.1% increase.

The latest CDC numbers show a 6.1% increase of measles cases from week-to-week. This is a slight increase in the percentage of cases from last week where there was a 5.92% increase.

The latest CDC numbers show a 5.92% increase of measles cases from week-to-week. This is a decrease in the percentage of cases from last week where there was a 9.18% increase.

The latest CDC numbers show a 9.18% increase of measles cases from week-to-week. This is an increase in the number of cases from last week where there was a 6.3% increase.

In this month's column, we look at the leadership change at CDC, an amicus brief supporting the AAP's lawsuit against HHS changes to the pediatric vaccine schedule, and potential clinical repercussions around the reports the federal government is considering removing the COVID-19 vaccine from the market.

In the final episode, the panelists offer some insights around following the federal agencies' ever-changing vaccine policies and the value of following professional medical societies' guidance during this period of uncertainty.

In this episode, the panelists discuss the potential concerns around changing vaccine guidelines and the importance of the American Academy of Pediatrics (AAP) stepping in to offer their recommendations.

The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) was supposed to convene this week to discuss COVID-19 vaccines. However, a district court’s decision to block recent vaccine policy changes has delayed the committee's meeting amid ongoing controversy over immunization guidance and rising public health concerns such as measles outbreaks. Here is some commentary on the inner workings of the current ACIP.

A district court judge has ruled against the current administration's vaccine policies and throws into jeopardy this week’s Advisory Committee on Immunization Practices meetings that were scheduled to discuss COVID-19 vaccines.

In this episode, the panelists discuss the probability that with vaccine recommendations changing across states and federally, costs could shift to families and increase health disparities.

The latest CDC numbers show a 6.3% increase of measles cases from week-to-week. This is a decrease in the number of cases from last week where there was a 12.76% increase.

In this episode, the panelists talk about how they broach conversations with expectant mothers around counseling on vaccinations for their babies.

The FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted for a trivalent vaccine composition for use in the US, protecting against influenza A (H1N1 and H3N2) and influenza B (Victoria lineage).

In this episode, the panelists discuss how the pediatric immunization schedule changes could potentially influence vaccines' inequities, and how vaccine education continues to play a significant role in immunization uptake and improving health equity.

In this episode, the panel discusses the continued importance of getting all children vaccinated and the potential unintended consequences of fewer individuals being immunized if the current trends continue.

The rate of HBV vaccination of newborns in the US has declined by over 10% in the past 2 years, reversing decades of increasing coverage.

The FDA’s biologics center faces another leadership shake-up as Vinay Prasad, MD, MPH, plans an exit in April, leaving questions over vaccine rules and gene-therapy approvals.